Last reviewed · How we verify
Sodium warfarin
Sodium warfarin is a Vitamin K antagonist (coumarin anticoagulant) Small molecule drug developed by University of Padova. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis. Also known as: Vitamin K antagonists, Oral anticoagulants.
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation.
Sodium warfarin is a vitamin K antagonist used to prevent and treat conditions such as thromboembolism and venous thromboembolism. It is also studied in clinical trials for conditions like aortic valve diseases and type 2 diabetes.
At a glance
| Generic name | Sodium warfarin |
|---|---|
| Also known as | Vitamin K antagonists, Oral anticoagulants |
| Sponsor | University of Padova |
| Drug class | Vitamin K antagonist (coumarin anticoagulant) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin is a coumarin anticoagulant that acts as a vitamin K antagonist. It inhibits the enzyme vitamin K epoxide reductase, which is essential for the carboxylation and activation of vitamin K-dependent clotting factors. This results in decreased synthesis of functional factors II, VII, IX, and X, prolonging the prothrombin time and reducing the risk of thromboembolism.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Mechanical heart valve thromboprophylaxis
- Post-myocardial infarction thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Warfarin-induced skin necrosis
- Nausea
- Alopecia
- Rash
Key clinical trials
- A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF (PHASE4)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- SWITCH: Apixaban vs Vitamin K in HM3 (PHASE3)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- Personalized Medicine Decision-Making in a Virtual Clinical Setting
- The PEERLESS II Study (NA)
- Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation (NA)
- LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium warfarin CI brief — competitive landscape report
- Sodium warfarin updates RSS · CI watch RSS
- University of Padova portfolio CI
Frequently asked questions about Sodium warfarin
What is Sodium warfarin?
How does Sodium warfarin work?
What is Sodium warfarin used for?
Who makes Sodium warfarin?
Is Sodium warfarin also known as anything else?
What drug class is Sodium warfarin in?
What development phase is Sodium warfarin in?
What are the side effects of Sodium warfarin?
What does Sodium warfarin target?
Related
- Drug class: All Vitamin K antagonist (coumarin anticoagulant) drugs
- Target: All drugs targeting Vitamin K epoxide reductase complex 1 (VKORC1)
- Manufacturer: University of Padova — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Indication: Drugs for Mechanical heart valve thromboprophylaxis
- Also known as: Vitamin K antagonists, Oral anticoagulants
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing